BioLife Solutions, Inc.
NASDAQ•BLFS
CEO: Mr. Roderick de Greef
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 1989-11-22
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Contact Information
3303 Monte Villa Parkway, Suite 310, Bothell, WA, 98021, United States
425-402-1400
Market Cap
$1.18B
P/E (TTM)
-365.0
74.9
Dividend Yield
--
52W High
$29.62
52W Low
$19.10
52W Range
Rank62Top 92.6%
1.9
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$28.07M-8.19%
4-Quarter Trend
EPS
$0.01-127.10%
4-Quarter Trend
FCF
$2.80M-24.02%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Revenue Growth Strong Nine months revenue reached $77.43M, marking a 30% increase driven by product sales.
Operating Cash Flow Improved Net cash provided by operating activities was $15.20M for nine months, up from $6.79M prior.
Equity Position Strengthened Total shareholders' equity grew to $353.74M as of September 30, 2025, up from year-end 2024.
PanTHERA Acquisition Expensed Immediate $15.5M IPR&D expense recognized following the April 2025 PanTHERA asset acquisition.
Risk Factors
Operating Loss Widened Nine months operating loss deteriorated to $(17.95M) compared to $(5.02M) in the prior period.
Deferred Tax Asset Risk Management projects a full $56.8M valuation allowance against U.S. deferred tax assets due to uncertainty.
Contingency Loss Recorded Recorded $1.4M loss contingency related to customer claims from the discontinued Global Cooling business.
Term Loan Maturity Near Remaining Term Loan principal of $7.50M matures in June 2026, requiring future financing action.
Outlook
SAVSU Divestiture Completed SAVSU Transaction closed October 6, 2025, for $25.5M; accounting for divestiture is not yet finalized.
Sufficient Liquidity Expected Current cash levels are believed sufficient to meet liquidity needs for at least the next twelve months.
R&D Investment Increased Research and development expenses rose 27% for nine months, driven by increased personnel costs.
Stock Comp Costs Remaining $0.9M unrecognized non-cash compensation cost remains for performance-based awards vesting over 0.2 years.
Peer Comparison
Revenue (TTM)
STAA$94.91B
$880.32M
NVCR$642.27M
Gross Margin (Latest Quarter)
85.2%
STAA82.2%
NVCR73.2%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| NEOG | $2.01B | -3.3 | -26.9% | 23.6% |
| ESTA | $1.96B | -24.1 | -253.8% | 77.1% |
| AZTA | $1.84B | -30.8 | -3.5% | 2.5% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
-63.2%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Mar 2, 2026
EPS:-$0.02
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 6, 2025|Revenue: $28.07M-8.2%|EPS: $0.01-127.1%BeatForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 7, 2025|Revenue: $25.42M+28.9%|EPS: $-0.33-26.7%MissForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 8, 2025|Revenue: $23.94M+29.9%|EPS: $-0.01-95.7%BeatForm 10-K/A - FY 2024
Period End: Dec 31, 2024|Filed: Apr 8, 2025|Revenue: $82.25M-42.6%|EPS: $-0.44+71.1%MissForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Mar 3, 2025|Refer to amended dataForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 12, 2024|Revenue: $30.57M+29.7%|EPS: $-0.04-94.5%BeatForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 9, 2024|Revenue: $19.72M-50.1%|EPS: $-0.45+95.7%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 10, 2024|Revenue: $18.43M-51.1%|EPS: $-0.22-31.3%Meet